Leon Cooperman founded Omega Advisors in 1991 after 25 years at Goldman Sachs. He is a more eclectic investor than Warren Buffett, and will buy any stock or bond at the right price if the company has honest management, he told Forbes in 2009. As a long-term investor, stocks that are fundamentally mispriced appeal to him. While at Columbia University’s business school, he studied security analysis under value investor Roger Murray. He recently wrote an open letter to President Obama criticizing his “divisive, polarizing” tone of his class rhetoric. In the fourth quarter, he took advantage of price dips to purchase 18 new stocks. His biggest buys were: Express Scripts Inc. (ESRX), Warnaco Group Inc. CL A (WRC), PVH Corp. (PVH) Medco Health Solutions Inc. (MHS).
Express Scripts Inc. (ESRX)
Express Scripts is a pharmacy benefit manager that generates revenue through delivering prescription drugs through its network of contracted retail pharmacies, specialty pharmacy services, home delivery and EM services.
Top 5 Gas Utility Stocks To Buy Right Now: Clovis Oncology Inc (CLVS)
Clovis Oncology, Inc. (Clovis) incorporated on April 20, 2009, is a Development-stage Company. The Company is a Biopharmaceutical Company. The Company focuses on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company also focuses on the treatment of specific subsets of cancer populations. During the year ended December 31, 2010, the Company was in the process of developing three product candidates for which it holds global marketing rights: CO-101, a lipid-conjugated form of the anti-cancer drug gemcitabine; CO-1686, an oral epidermal growth factor receptor (EGFR) mutant-selective inhibitor and CO-338, a poly ADP (Adenosine Diphosphate)-ribose polymerase (PARP) inhibitor. Effective November 19, 2013, Clovis Oncology Inc acquired the entire share capital of Ethical Oncology Science SpA.
CO-101 – a Lipid-Conjugated Form of the Anti-Cancer Drug Gemcitabine
CO-101 is designed to treat patients with pancreatic cancer whose tumors express low amounts of a membrane transporter protein on the surface of the cancer cell known as hENT1 and are thus expected to be resistant to standard gemcitabine-based therapy. Based on the published results of multiple studies assessing the correlation of hENT1 expression to survival outcomes in pancreatic cancer patients treated with gemcitabine, the Company estimates that approximately 40% to 50% of pancreatic patients express low levels of hENT1, and thus derive little or no benefit from gemcitabine therapy. CO-101 is in an international, randomized and controlled 360-patient study for the first-line treatment of metastatic pancreatic cancer. This open-label study compares CO-101 to gemcitabine as a first-line therapy in patients with metastatic pancreatic cancer. Clovis is partnered with Ventana Medical Systems for the development and commercialization of a companion diagnostic for the assessment of hENT1 levels.
CO-1686-an Oral EGFR Mutant-Selective ! Inhibitor
CO-1686 is an orally available, small molecule covalent inhibitor of the cancer-causing mutant forms of EGFR for the treatment of non-small cell lung cancer (NSCLC). CO-1686 targets both the initial activating EGFR mutations as well as the primary resistance mutation, T790M, it treats both first- and second-line NSCLC patients with EGFR mutations. Such initiating activating mutations occur in approximately 10% to 15% of NSCLC cases in Caucasian patients and approximately 30% to 35% of NSCLC cases in East Asian patients. Following treatment with approved NSCLC therapies, Tarceva (erlotinib) or Iressa (gefitinib), both known as tyrosine kinase inhibitors (TKIs), approximately half of these patients develop the T790M mutation.
The Company focuses on the development of CO-1686 as both a second-line therapy for EGFR-mutated NSCLC patients who become resistant to TKIs due to the emergence of the T790M secondary mutation and as a first-line trea tment for EGFR-mutated NSCLC. Clovis is partnered with Roche Molecular Systems for the development and commercialization of a companion diagnostic for identification of EGFR mutations.
CO-338-a PARP Inhibitor
CO-338 is a small molecule PARP inhibitor that the Company focuses to develop as both monotherapy and in combination with chemotherapeutic agents for the treatment of selected cancer patients. CO-338 is in a Phase I clinical trial to determine the maximum tolerated dose of oral CO-338 that can be combined with intravenous, or IV, platinum chemotherapy in the treatment of solid tumors. This program is supplemented by two ongoing investigator-initiated trials, using the IV formulation of CO-338: a Phase I/II study in germ-line BRCA mutant breast and ovarian cancer and a Phase II study in the adjuvant treatment of germ-line BRCA mutant and triple-negative breast cancer. The Company also focuses on initiating a Phase I monotherapy study of the oral formulation, to determine an appropriate dose and schedule.!
The Company competes with Eli Lilly, Teva Pharmaceutical Industries, APP Pharmaceuticals, AB Science SA, Amgen Inc., Astellas Pharma, BioSante Pharmaceuticals, Inc., Celgene Corporation, Immunomedics, Inc., Lorus Therapeutics, Threshold Pharmaceuticals, Inc., Boehringer Ingelheim, Pfizer, Sanofi-Aventis, Astra Zeneca, Abbott, Merck, Eisai, Cephalon and Biomarin.
- [By John Kell and Lauren Pollock var popups = dojo.query(“.socialByline .popC”); ]
Clovis Oncology(CLVS) posted positive findings from a study of a lung-cancer treatment. The Phase 1 study of the oral treatment, called CO-1686, demonstrated “encouraging” results and progression-free survival in patients, Clovis said. Shares increased 4.2% to $80.75 in recent premarket trading.
- [By Jake L’Ecuyer]
Clovis Oncology (NASDAQ: CLVS) was also up, gaining 7.26 percent to $79.35 after the company announced 2014 objectives and financial outlook. The company projected to initiate three global registration studies for CO-1686.
- [By John Udovich]
On Wednesday, small cap cancer stock Clovis Oncology Inc (NASDAQ: CLVS) soared 16.68% after announcing a $200 million cancer deal plus the biotech has more than tripled since late 2011, meaning it might be time to take a closer look at what’s driving the stock higher as well as look at the performance of biotech ETF benchmarks like iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB) and SPDR S&P Biotech ETF (NYSEARCA: XBI).
- [By John Udovich]
Bubble talk, biotech IPO setbacks plus news about small cap biotechs like Intrexon Corp (NYSE: XON) and TNI BioTech (OTCMKTS: TNIB) have dominated biotech news this week or in recent weeks. Just consider the following news:
Why There is No Biotech Bubble & Where to Look for Value in Biotech. Marshall Gordon, the Director and senior health-care analyst of ClearBridge Investments, was recently interviewed by Barron’s where he stated his belief that there is no biotech bubble because biotech stocks have delivered new drugs and have shown an ability to innovate. With that said, he added that the sector got ahead of itself while some biotechs suffered setbacks plus hedge funds decided to trim risk from their portfolios. Nevertheless, Marshall likes or is watching mid cap biotechs BioMarin Pharmaceutical Inc (NASDAQ: BMRN) and Pharmacyclics, Inc (NASDAQ: PCYC) along with small cap biotechs Pacira Pharmaceuticals Inc (NASDAQ: PCRX) and Clovis Oncology Inc (NASDAQ: CLVS). He also added that recent biotech IPOs have been lesser quality names than earlier offerings. A Trio of Biotech IPO Setbacks. FierceBiotech has summarized how a trio of biotech IPO have suffered setbacks. Specifically, Relypsa (NASDAQ: RLYP), a late-stage biotech developing a treatment for hyperkalemia, slashed its asking price on 6.9 million shares to $12 a share to raise $82 million from a range of $16 to $19 a share while Xencor (NASDAQ: XNCR), a biotech developing antibodies for severe autoimmune/allergic diseases and cancer, has dropped its IPO price to $7 a share to raise $75 million from a range of $14 to $16. Meanwhile, Celladon, which is developing a first-in-class gene therapy for patients with systolic heart failure, has postponed its IPO citing poor market conditions. Coming Biotech IPOs. Nevertheless, FierceBiotech has noted that GeNO Healthcare (NASDAQ: GNO) is looking to raise $50 million for its new, patient-friendly approach for delivering inhaled nitric oxide on the
Top 5 Gas Utility Stocks To Buy Right Now: American Vanguard Corp (AVD)
American Vanguard Corporation, incorporated on January 2, 1969, operates as a holding company. The Company is primarily a chemical manufacturer that develops and markets products for agricultural and commercial uses. The Company manufactures and formulates chemicals for crops, human and animal protection. The Company conducts its business through its subsidiaries, AMVAC Chemical Corporation (AMVAC), GemChem, Inc. (GemChem), 2110 Davie Corporation (DAVIE), Quimica Amvac de Mexico S.A. de C.V. (AMVAC M), AMVAC de Costa Rica Sociedad Anonima (AMVAC CR), AMVAC Switzerland GmbH (AMVAC S), AMVAC do Brasil Representacoes Ltda (AMVAC B), AMVAC Chemical UK Ltd. (AMVAC UK), AMVAC CV (AMVAC CV), AMVAC Netherlands BV (AMVAC BV), and Envance Technologies, LLC (Envance). In July 2012, the Company completed the restructuring of the International Sales & Marketing function of its principal operating subsidiary, AMVAC Chemical Corporation. On November 30, 2012, AMVAC and TyraTech, Inc. for med Envance Technologies, LLC, in which the Company owns 60% of the equity interest. In July 2012, the Company formed AMVAC CV and AMVAC BV.
AMVAC is a chemical manufacturer that develops and markets products for agricultural and commercial uses. It manufactures and formulates chemicals for crops, human and animal health protection. These chemicals, which include insecticides, fungicides, herbicides, molluscicides, growth regulators, and soil fumigants, are marketed in liquid, powder, and granular forms. AMVAC owns and/or operates the Company’s domestic manufacturing facilities and is also the parent company for all its foreign companies. DAVIE owns real estate for corporate use.
GemChem is a national chemical distributor. GemChem, in addition to purchasing key raw materials for the Company, also sells into the pharmaceutical, cosmetic and nutritional markets. GemChem is a wholly owned subsidiary of AVD.
- [By Travis Hoium]
What: Shares of specialty chemical maker American Vanguard (NYSE: AVD ) jumped 10% today after the company released earnings.
So what: First-quarter revenue jumped 39% to $121.5 million and adjusted earnings per share nearly doubled to $0.59. Analysts only expected $115.4 million in revenue and earnings of $0.46 per share so the company easily beat on both the top and bottom line.
- [By Seth Jayson]
Margins matter. The more American Vanguard (NYSE: AVD ) keeps of each buck it earns in revenue, the more money it has to invest in growth, fund new strategic plans, or (gasp!) distribute to shareholders. Healthy margins often separate pretenders from the best stocks in the market. That’s why we check up on margins at least once a quarter in this series. I’m looking for the absolute numbers, so I can compare them to current and potential competitors, and any trend that may tell me how strong American Vanguard’s competitive position could be.
Top 5 Gas Utility Stocks To Buy Right Now: Electronics for Imaging Inc.(EFII)
Electronics For Imaging, Inc. provides color digital print controllers, digital inkjet printers, and business process automation solutions. The company?s Fiery products consist of stand-alone print controllers and servers connected to digital copiers and other peripheral devices; embedded and design-licensed solutions used in digital copiers and multi-functional devices; optional software integrated into controller solutions that include Fiery Central and MicroPress; Entrac, a self-service and payment solution; PrintMe, a mobile printing application; and stand-alone software-based solutions, such as proofing and scanning solutions, including ColorProof XF, Fiery XF, ColorProof eXpress, and Xflow. It also offers industrial inkjet products, including VUTEk super-wide format digital industrial inkjet printers and inks used by billboard graphics printers, commercial photo labs, sign shops, graphic screen printers, specialty commercial printers, and digital graphics providers; Rastek hybrid and flatbed entry level production UV wide format inkjet printers; and Jetrion label and packaging digital inkjet printers, integration solutions, and specialty digital UV inks for primary and secondary label applications, and industrial label or flexible packaging markets. In addition, the company provides advanced professional print software products consisting of print production workflow and management information software, including Monarch, PSI, Logic, PrintSmith, and PrintFlow; Pace, a cloud-based business process automation software; and cloud-based order entry and order management systems, which comprise Digital StoreFront, PrinterSite, and PrintSmith Site. Electronics For Imaging, Inc. offers its products through sales force and distribution arrangements primarily in the Americas, Europe, the Middle East, Africa, and Japan. The company was founded in 1988 and is headquartered in Foster City, California.
- [By shash63]
Electronic For Imaging’s (EFII) second biggest segment, Fiery Controllers, contributed 35% of total revenue. This segment provides controllers for digital printers. The company’s big clients in this segment are Xerox, Ricoh, Konica Minolta, and Canon, contributing 80% of this segment’s revenue. These clients are expected to launch new products in future, thus creating further potential for revenue growth.
- [By Brian Pacampara]
What: Shares of digital printing technologist Electronics for Imaging (NASDAQ: EFII ) popped 12% today after its quarterly results topped Wall Street expectations.
- [By Seth Jayson]
Electronics for Imaging (Nasdaq: EFII ) reported earnings on April 18. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), Electronics for Imaging beat expectations on revenues and beat expectations on earnings per share.
Top 5 Gas Utility Stocks To Buy Right Now: Kawasaki Heavy Industries Ltd (KWHIY)
Kawasaki Heavy Industries Ltd (KHI), incorporated on October 15, 1896, is a global manufacturer of transportation equipment and industrial goods. KHI manufactures ships, rolling stock, aircraft and jet engines, gas turbine power generators, environmental and industrial plants, and range of manufacturing equipment and systems. KHI also produces consumer products, such as Kawasaki-brand motorcycles and personal watercraft. KHI’s business is divided into seven operations: shipbuilding, rolling stock and construction machinery, aerospace, gas turbines and machinery, plant and infrastructure engineering, consumer products and machinery, and hydraulic machinery.
Kawasaki Shipbuilding Corporation, which is the company of this segment, is engaged in building gas carriers and submarines, which require advanced design and construction technologies. It offers
a range of liquefied natural gas (LNG) carriers, extending from small carriers with cargo tank capacitie s of 19,000 cubic meters to large carriers with capacities of 177,000 cubic meters. It also developed and offered in its lineup a pressure build-up type LNG carrier for short distance and small-volume transportation. The Company’s shipbuilding operations include products, such as LNG carriers, liquefied petroleum gas (LPG) carriers, container ships, very large crude carriers (VLCCs) and other types of tankers, bulk carriers, high speed vessels, submarines, maritime application equipment.
KHI’s rolling stock production systems are located in Hyogo and Harima in Japan and in Lincoln, Nebraska, and Yonkers, New York, in United States. Kawasaki completed its light rail vehicle (LRV), dubbed SWIMO. It also is developing efSET (Environmentally Friendly Super Express Train) which achieves a service speed of 350 kilometers per hour (km/h). Regarding the construction machinery business, Kawasaki has arranged a business alliance with Hitachi Construction Machinery Co ., Ltd., and TCM Corporation. As of April 1, 2009, the Compa! ny split off its construction machinery business as a wholly owned subsidiary of KHI, KCM Corporation.
KHI is the prime contractor for the development of the MOD’s large-scale XP-1 and C-X aircraft. In the commercial aircraft field, KHI delivered a test model of Boeing’s 787 Dreamliner passenger aircraft. KHI is a partner corporation in the development and production of the 787 Dreamliner.
The Gas Turbines & Machinery segment has a range of products for the energy and transportation equipment field. KHI focuses to expand its global business by offering solutions for its customers that include a lineup of in-house developed gas turbines together with product support and maintenance. During the year ended December 31, 2008, the 8MW-class power-generating capacity Kawasaki Green Gas Engine had 4,000 hours of operational testing.
The plant and infrastructure engineering segment encompasses the operations of Kawasaki Plant Systems, Lt d. (K Plant), which undertakes projects to supply energy-related, industrial infrastructure, environmental preservation systems and equipment, and the operations of the parent company’s Industrial Facilities and Tunneling Equipment Division, which mainly focuses on LNG tanks and diverse other storage tanks along with shield machines and tunnel-boring machines. The Anhui Conch Kawasaki Energy Conservation Equipment Manufacturing Co., Ltd. (CKM) is engaged in the manufacturing of PH boiler parts that are employed in waste heat power plants. CKM has commenced the manufacturing and sales of environmental preservation related products, including cement plant components, such as vertical mills, boilers for waste heat recovery power generation systems, and waste gasification systems and sewage treatment systems that can be integrated with cement kilns to enable municipal waste recycling.
The consumer products and machinery segment includes the manufacture of motorcyc les, all terrain vehicles (ATVs), utility vehicles, personal! watercra! ft, general purpose gasoline engines and industrial robots. In the motorcycle line, Kawasaki launched the ZRX1200 DAEG and the Ninja ZX-6R. In the cruiser segment, Kawasaki launched its Vulcan 1700 series with developed engine and chassis. This series includes the Vulcan 1700 Voyager, a full-dress V-twin engine tourer with a load of long-distance touring equipment. In the utility vehicle category, KHI equipped the Teryx 750 series with an electronic fuel injection system, mainly for recreational use. The MULE utility-oriented vehicle series was restyled with the launch of the MULE 4010 series.
The hydraulic machinery operations include Kawasaki Precision Machinery Ltd. (KPM). It has five manufacturing and marketing facilities, which comprises KPM’s headquarters plant and the facilities
of Kawasaki Precision Machinery (U.K.) Limited; Kawasaki Precision Machinery (U.S.A.), Inc.; China based Kawasaki Precision Machinery (Suzhou) Ltd.; and Korea-based Flute k, Ltd.
- [By WWW.MARKETWATCH.COM]
LOS ANGELES (MarketWatch) — Japanese stocks have ended with losses in every session this week, and sure enough, the Nikkei Average (JP:NIK) was down 0.6% in early Friday trade, though off an opening 0.8% defecit, while the Topix carried a 0.7% loss. Overnight losses for the U.S. and further strength in the yen (with the dollar falling to ¥101.28 from ¥101.56 a day earlier) helped drag the market lower, as did results from Fast Retailing Co. (JP:9983) (FRCOF) , the shares of which hold the heaviest weighting on Nikkei Average. Fast Retailing said that while its Uniqlo brand was doing great business, weakness for its J Brand luxury demin label helped send September-May profit down 4% and prompted another cut to Fast’s full-year outlook. Consequently, its shares traded 0.7% lower, though rivals Takashimaya Co. (JP:8233) and J. Front Retailing Co. (JP:3086) (JFROF) also saw losses of 0.6% and 0.5%, respectively. Among other decliners, Sony Corp. (JP:6758) (SNE) lost 0.7%, Toshiba Corp. (JP:6502) (TOSYY) fell 2.1%, Kawasaki Heavy Industries Ltd. (JP:7012) (KWHIY) fell 1.5%, Toyota Motor Corp. (JP:7203) (TM) and Nissan Motor Co. (JP:7201)
Top 5 Gas Utility Stocks To Buy Right Now: PrimeEnergy Corporation(PNRG)
PrimeEnergy Corporation, through its subsidiaries, engages in the acquisition, exploration, development, and production of crude oil and natural gas in the United States. Its principal properties are located in Texas, Oklahoma, West Virginia, the Gulf of Mexico, New Mexico, Colorado, and Louisiana. The company operates 1,600 oil and gas wells, as well as owns non-operating interests in approximately 800 additional wells. It also provides well-servicing support operations, site-preparation, and construction services for oil and gas drilling and reworking operations, as well as contract services for third parties. In addition, the company involves in the acquisition of producing oil and gas properties through joint ventures with industry partners. As of December 31, 2010, it had proved reserves of 101 billion cubic feet of gas equivalent. The company was founded in 1973 and is based in Stamford, Connecticut.
- [By Jake L’Ecuyer]
Leading and Lagging Sectors
Energy shares declined by just 0.08 percent in Monday’s trading. However, top gainers in the sector included PrimeEnergy (NASDAQ: PNRG) and Dresser-Rand Group (NYSE: DRC). In trading on Monday, financial shares were relative laggards, down on the day by about 1.07 percent.